Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483625 · ClinicalTrials.gov registry record · Phase 4
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT01483625 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 140 participants.
The verdict
NCT01483625, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms. It also represents an opportunity to identify COPD patients earlier in their disease state and start maintenance therapy, if appropriate.
Interventions
- DRUG Placebo
- DRUG tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01483625
The ClinicalTrials.gov registry entry for NCT01483625 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01483625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01483625 about?
NCT01483625 is a clinical study titled "Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection". The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms. It also represents an opportunity to identify COPD patients earlier in their disease state and st...
What is the current status of trial NCT01483625?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2011-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01483625?
The interventions under investigation include: Placebo (DRUG), tiotropium (DRUG).
Who is sponsoring clinical trial NCT01483625?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.